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Abstract
Background: To investigate the prognostic significance of patient characteristics and clinical laboratory test results
in locally advanced non-small cell lung cancer (NSCLC), and in particular the impact of diabetes mellitus (DM) on
the survival of patients who underwent chemoradiotherapy.
Methods: We retrospectively reviewed 159 patients with locally advanced NSCLC with a focus on DM and other
potential prognostic factors, using the log-rank test, and univariate and multivariate analyses to assess their
association with survival.
Result: Five significant prognostic factors were identified in univariate analysis: stage (p < 0.001), DM (p = 0.04),
hemoglobin levels (p = 0.003), serum albumin (p <0.001) and lactate dehydrogenase (LDH) levels (p = 0.01).
Furthermore, among the factors tested using Fisher's exact test and the Wilcoxon rank sum test, gender (p = 0.019) and
plasma glucose level (p <0.001) were found to have prognostic significance. Multivariate analysis showed that stage,
DM, serum albumin and LDH levels were independent prognostic factors for survival (p = 0.007, p = 0.024, p = 0.007 and
p = 0.005, respectively).
Conclusions: The presence of DM at the time of diagnosis was identified as an independent and significant
prognostic factor for predicting negative outcome in locally advanced NSCLC patients.
Keywords: Locally advanced, Non-small cell lung cancer, Prognostic factors, Diabetes mellitus, Serum factors
Background
Lung cancer is the most common type of cancer, both
worldwide and in Japan [1]. Non-small cell lung cancer
(NSCLC) accounts for 80–85 % of lung cancer cases,
and approximately 30 % of patients have unresectable,
locally advanced disease at diagnosis [2]. Sause et al. re-
ported that combining chemotherapy and radiotherapy
brought a further survival benefit [3]. A recent meta-
analysis concluded that concurrent chemoradiotherapy
(CRT) is the most effective treatment for these patients
[4], and CRT is currently the recommended standard
first-line treatment for locally advanced NSCLC. Stage
III NSCLC constitutes a heterogeneous group, probably
due to a varying extent of nodal involvement. The me-
dian survival of patients with stage III NSCLC has re-
cently been revised from 12 to 23.3 months based on
the findings of phase III trials [5, 6].
A number of very different prognostic factors in several
trials have been identified for the survival of patients with
NSCLCs [7–15]. Various studies have indicated that
among patients with colorectal, pancreatic, breast, or liver
cancer, existing diabetes mellitus (DM) was associated
with a lower chance of long-term survival [16–19]. It has
also been found that good performance status (PS), dis-
ease stage, age and weight loss are strong prognostic fac-
tors in this malignancy. Although the prognostic
significance of pre-existing DM in patients with lung
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cancer was evaluated in a number of studies [20–27], their
findings were inconsistence. Three studies reported a
shorter survival for patients with DM compared to those
without DM [20–22]. On the other hand, several studies
have shown that DM was associated with an equal or lon-
ger survival [23–27]. Thus the prognostic significance of
DM in NSCLC remains uncertain.
The aim of this study was to investigate the impact of
DM on the survival of patients with locally advanced
NSCLC who received first-line CRT.
Methods
Patient population
We retrospectively reviewed the clinical records of 159
patients with clinical stage III NSCLC who were treated
with concurrent CRT at the Shizuoka Cancer Center be-
tween September 2002 and December 2009. The eligibil-
ity criteria of this study were as follows: (1) histologically
or cytologically proven NSCLC; (2) chemoradiotherapy
naïve; (3) age ≤ 75 years; (4) Eastern Cooperative Oncol-
ogy Group (ECOG) PS of 0 to 2; and (5) treated with
curative thoracic radiotherapy over 50Gy concurrent
with platinum doublet chemotherapy. Sixteen potential
prognostic variables were chosen on the basis of previ-
ously published clinical trials [7–14]. Baseline character-
istics, including the presence of DM, gender, age, PS,
clinical stage, histology, smoking history, body mass
index (BMI), laboratory parameters, radiation dose, and
chemotherapy regimens were obtained retrospectively
from the medical charts. Some variables were divided
into categories: gender (male or female), PS (0 or 1),
clinical stage (IIIA or IIIB), histology (adenocarcinoma
or non-adenocarcinoma, squamous cell carcinoma or
non-squamous cell carcinoma), smoking history (never
or former/current) and DM (present or absent) at the
start of CRT. Patients were identified as having DM on
the basis of an elevated fasting glucose level (>126 mg/
dL), and a history of DM or medication use, such as in-
sulin or oral hypoglycemic agents. All patients under-
went systematic evaluation and standardized staging
procedures before the start of treatment. Clinical stage
was assigned based on the results of physical examin-
ation, chest radiography, computed tomography (CT)
scans of the chest and abdomen, CT or magnetic reson-
ance imaging (MRI) of the brain, and bone scintigraphy
or positron emission tomography (PET). Patients with
distant or contralateral hilar lymph node metastases
were excluded from this analysis. The histologic classifi-
cation of the tumor was based on the criteria of the
World Health Organization [28]. Our study is conducted
according to STROBE guidelines, and we ensure this
statement. And this study has been approved by the
institutional review board of Shizuoka cancer center
(ethical committee for clinical studies- Shizuoka cancer
center) and has therefore been performed in accordance
with the ethical standards laid down in the 1964 Declar-
ation of Helsinki and its later amendments.
Treatment methods
Radiotherapy was administered using 6- or 10-MV X-
rays in 2-Gy fractions 5 times weekly. All patient treat-
ment plans were designed based on a 3-dimensional
treatment planning system. The gross tumor volume
was delineated according to nodal involvement deter-
mined by CT. The clinical target volume was defined
and contoured with 5–10 mm around the gross tumor
volume and contours around the regional lymph node
regions, i.e., the ipsilateral hilum and the mediastinum.
Planning target volume (PTV) 1 comprised the clinical
target volume plus a 5 to 10 mm margin; PTV 2 in-
cluded the gross tumor volume plus a 10 mm margin.
An additional margin was added if necessary. Beam
shaping was performed using a multileaf collimator. The
standard of practice was to prescribe 60 Gy to PTV 2
and 40 Gy to PTV 1. Other objectives were to restrict
the relative volume of the normal lung exposed to a ra-
diation dose >20 Gy (V20) to ≤35 %, and the maximum
spinal cord dose was restricted to <44 Gy. The dose was
prescribed to the isocenter of this point. The chemother-
apy regimen was determined by the treating physician.
Assessment of outcomes and statistical analysis
Radiographic tumor responses were evaluated accord-
ing to the Response Evaluation Criteria in Solid
Tumors, ver. 1.1 [29]. All of the analyses were per-
formed using the JMP statistical software program
package (JMP version 9.0 for windows). To explore
prognostic factors for Overall survival (OS), the pro-
portional hazards model with a stepwise regression
procedure was applied. Hazard ratios (HR) and 95 %
confidence intervals (CIs) were estimated using the
model. Because the HR is defined for a 1-unit differ-
ence, some factors were converted to an appropriate
scale unit. Progression-free survival (PFS) was calcu-
lated from the start of treatment to the date of PD or
death from any cause. OS was calculated from the
start of the first cycle of chemotherapy to the date of
death from any cause or the date of the last follow-
up, and was estimated using the Kaplan-Meier
method. The Fisher’s exact test and Wilcoxon rank
sum tests were used to compare the mean values of
the variables of the two groups studied. The Cox pro-
portional hazards regression model was used to deter-
mine the statistical significant of the variables related
to survival. Differences were assumed to be significant
when the p value was less than 0.05.
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Results
Patient characteristics
One hundred and fifty-nine patients with clinical stage
III NSCLC were enrolled in this study. The patients’
baseline characteristics are listed in Table 1. There were
30 patients with DM and 129 without DM. The median
age of patients was 64 years (range, 40–75 years), with
126 (79.2 %) men and 33 (20.8 %) women. Eighty-six pa-
tients (54.1 %) were diagnosed as having stage IIIA and
73 patients (45.9 %) stage IIIB disease. As shown in
Table 2, 6, 107, 39 and 5 of all 159 patients showed
complete response (CR), partial response (PR), stable
disease (SD), and progressive disease (PD), respectively.
The response rate was 71.1 % and the disease control
rate was 96.8 %. The estimated median PFS was
11.6 months and the median OS was 38.0 months
(Fig. 1a and b).
Prognostic factor analysis
The results of univariate analysis are summarized in
Table 3. Among the 16 factors analyzed, five were identi-
fied as having prognostic significance: stage (p < 0.001),
DM (p = 0.04), hemoglobin levels (p = 0.003), serum al-
bumin (p <0.001) and lactate dehydrogenase (LDH)
levels (p = 0.01). OS was longer amongst patients with-
out DM than with DM (median, 40.3 versus 36.4 months;
HR, 1.66; 95 % CI, 1.01–2.63; p = 0.031) (Table 4). Fur-
thermore, among the factors tested using Fisher's exact
test and Wilcoxon’s rank sum test, two were found to
have prognostic significance: gender (p = 0.019) and
plasma glucose level (p <0.001) (Table 5).
Multivariate analysis included the five factors identi-
fied as significant prognostic predictors by univariate
analysis (Table 6), and revealed that stage, DM, and
serum albumin and LDH levels were independent prog-
nostic factors for survival (p = 0.007, p = 0.024, p = 0.007
and p = 0.005, respectively).
Discussion
In this retrospective study, we sought to clarify the im-
pact of DM on the prognosis of patients with locally ad-
vanced NSCLC, and in particular the relationship
between DM and the OS of patients receiving chemora-
diotherapy. The prevalence of DM and cancer are both
increasing. In our study, the prevalence of DM amongst
locally advanced NSCLC patients was 18.9 %, about four
Table 1 Patient characteristics
Characteristic Number of
patients




Age (years), median (range) 64 (40–75)
Performance status 0 90
1 67
2 2
Clinical Stage IIIA 86
IIIB 73
Histology Adenocarcinoma 87
Squamous cell carcinoma 54
Large cell carcinoma 6
Others 12
Smoking history Current or former 119
Never 25
Unknown 15
Body mass index (BMI) (kg/m2) BMI < 18.5 15
18.5 ≤ BMI < 25 116
25 ≤ BMI < 30 26
BMI≥ 30 2
Laboratory parameters, median









Median (range) radiation dosage (Gy) 60 (46–74)
Chemotherapy regimen CDDP + VNR 44
CDDP + S1 46
CBDCA + PTX 46
Others 23
AST Alanine aminotransferase, AST Aspartate aminotransferase, LDH Lactate
dehydrogenase, CDDP Cisplatin, VNR Vinorelbine, CBDCA Carboplatin,
PTX Paclitaxel
Table 2 Response to chemoradiotherapy





Response rate (%) 71.1
Disease control ratea (%) 96.8
CR Complete response, PR Partial response, SD Stable disease, PD
Progressive disease
aCR + PR + SD
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times as high as the global prevalence of diabetes [30].
DM (mainly type 2 diabetes) is associated with an in-
creased risk of diverse cancers including those of the
liver, pancreas, endometrium, colon, rectum, breast, and
bladder [31]. Moreover, preexisting diabetes in cancer
patients at the time of diagnosis was associated with an
HR of 1.41 for the risk of all-cause mortality compared
to patients without diabetes in a pooled analysis of vari-
ous types of cancer. For instance, preexisting diabetes
was significantly associated with increased long-term,
all-cause mortality for cancers of the endometrium (HR,
1.76; 95 % CI, 1.34–2.31), breast (HR, 1.61; 95 % CI, 1.46–
1.78), and colorectum (HR, 1.32; 95 % CI, 1.24–1.41) [32].
DM is generally characterized by insulin resistance and
hyperinsulinemia [33], and insulin resistance is among the
hallmark conditions that characterize type 2 DM and leads
to hyperinsulinemia.
It has been reported that cancer patients with DM
have a poorer short- and long-term prognosis compared
to those without DM [32, 34]. However, only a few stud-
ies have addressed the impact of DM on the survival of
lung cancer patients [20–27]. The only available evi-
dence is limited and conflicting. Although several
reports suggested a shorter survival for patients with
DM compared to those without DM [20–22], several
others have shown that DM was associated with equal
or even prolonged survival [23–27]. These studies in-
cluded patients with metastatic NSCLC, and to our
knowledge, the present study is the first to evaluate the
relationship between DM and prognostic significance in
a sample limited to patients with locally advanced
NSCLC who underwent chemoradiotherapy.
The current study demonstrated that patients with
DM (n = 30) exhibited a significant increase in mortality
compared with those without DM (n = 129), and that
DM is an independent risk factor for survival. There
may be several reasons for this. First, insulin activates
the phosphoinositide 3-kinase (PI3K)/Akt and the Ras/
MAP kinase pathways via the insulin and IGF-1 recep-
tors. These pathways have been shown to stimulate cell
proliferation, metastasis and progression. Also, PI3K/Akt
pathway plays an important role in treatment resistance,
radioresistance and chemoresistance. PI3K/Akt pathway
is associated with three major radiation mechanisms (in-
trinsic radiosensitivity, proliferation and hypoxia). While
pAkt has been studied as prognostic factor in NSCLC,
inhibition of pAkt increased apoptosis and improved cel-
lular responsiveness to chemotherapy and irradiation in
NSCLC. The combination of EGFR inhibitor and PI3K/
Akt showed additive cytotoxicity [35, 36]. Insulin resist-
ance is a characteristic of type 2 DM and leads to hyper-
insulinemia. Excessive insulin action associated with
insulin resistance is thought to progress these multiple
cancer phenotypes. Hyperinsulinemia may also promote
carcinogenesis indirectly through its effects on IGF-1, as
insulin inhibits IGF-1 binding proteins and thus increases
the bioavailability of IGF-1. Second, hyperglycemia in-
creases superoxide production by inducing mitochondrial
dysfunction. Increased oxidative stress plays a pivotal role
in the development micro and macrovascular complica-
tions, and also increases the likelihood of DNA damage,
leading to an increased rate of mutations and changes in
cancer related gene expression. Since cancer cells are an-
aerobic in their metabolism, and thus require relatively
large amounts of glucose, the elevated glucose levels in
DM can promote cancer cell survival under hypoxic con-
ditions. Third, chronic inflammation is related to both
obesity and DM, and inflammation plays a role in every
stage of tumorigenesis, from initiation through to meta-
static progression. DM-related inflammation is promoted
by the activation of a number of signaling pathways, in-
cluding those dependent on interleukin-6, tumor necrosis
factor (TNF-a), NF kappa-B (NF-kB), STAT3 and adipo-
kines [31, 37–39]. Especially, STAT3 has been studied as
prognostic factor in NSCLC. STAT3 related to the sensi-
tivity to cytotoxic agents. In NSCLC cell line, overexpres-
sion of STAT3 mRNA levels showed cisplatin-resistance.
Fig. 1 a Kaplan-Meier plots showing progression-free survival (PFS).
Median PFS: 11.6 months. b Kaplan-Meier plots showing overall survival
(OS). Median OS: 38.0 months
Imai et al. BMC Cancer  (2015) 15:989 Page 4 of 8
By contrast, silenceing STAT3 demonstrated more sensi-
tive to the cytotoxic agents. Also, STAT3 plays a crucial
role in chemotherapy [40].
The findings of a previous study suggested that DM at
the time of diagnosis had no association with survival in
patients with SCLC [41], although small cell lung cancer
(SCLC) patients generally only survive for a short time
anyway, and hence survival may not be affected by the
presence of DM. In contrast, DM was found to be a
negative prognostic factor for the treatment of advanced
NSCLC [22], although at least half the patients in that
study had stage IV disease, and thus also had a poor
prognosis. In our study, we only included patients who
had stage III disease and who were treated with CRT,
and the median OS of this cohort was 38.0 months. As
these patients were in sufficiently good health to
undergo CRT, they correspondingly survived longer on
average than patients with stage IV disease. DM also
contributes to the longer-term outcome of tumors, and
the prognosis after CRT may be affected by relatively
long-term insulin resistance and hyperinsulinemia,
hyperglycemia, and chronic inflammation associated
with this condition. However, further research is needed
to clarify how DM affects the outcome after chemother-
apy in various types of human cancers.
Previous studies have compared the cancer risk among
different ethnic groups, and this revealed that Asian
Table 4 Association between OS and DM from univariate
analysis
Median OS (months) Hazard ratio 95 % CI p value
DM (−) 40.3 1.66 1.01–2.63 0.03
DM (+) 36.4
OS Overall survival, 95 % CI 95 % confidence interval, DM Diabetes mellitus
Table 3 Univariate Cox regression analysis of baseline patient characteristics
Overall survival
Factors Hazard ratio 95 % CI p value
Gender
Male/Female 1.2 0.80–2.11 0.30
Age 0.99 0.97–1.02 0.75
Performance status
0/1 1.24 0.84–1.83 0.26
Clinical stage
IIIA/IIIB 1.92 1.30–2.85 <0.001
Histology
Ad/Non-ad 0.74 0.50–1.09 0.13
Sq/Non-sq 1.19 0.79–1.76 0.37
Smoking history
Yes/No 1.39 0.82–2.25 0.19
Diabetes Mellitus
Yes/No 1.66 1.01–2.63 0.04
Body mass index (BMI) (kg/m2)
BMI < 18.5 / 18.5≤ BMI < 25 1.54 0.77–2.78 0.20
25 ≤ BMI < 30 + BMI≥ 30/18.5≤ BMI < 25 0.95 0.55–1.55 0.85
Laboratory parameters
White blood cell count 1 0.99–1.00 0.63
Hemoglobin 0.85 0.76–0.94 0.003
Albumin 0.4 0.26–0.62 <0.001
AST 1.01 0.99–1.03 0.22
ALT 1 0.99–1.02 0.33
LDH 1 1.00–1.05 0.01
Calcium 0.81 0.49–1.35 0.43
Creatinine 1.24 0.37–3.88 0.71
Glucose 0.99 0.98–1.00 0.37
95 % CI 95 % confidence interval, Ad Adenocarcinoma, Sq Squamous cell carcinoma, AST Alanine aminotransferase, AST Aspartate aminotransferase, LDH Lactate
dehydrogenase, Boldfaced p-values are statistically significant (p < 0.05)
Imai et al. BMC Cancer  (2015) 15:989 Page 5 of 8
men had a higher cancer risk than non-Asian men. In
this context, it is also noteworthy that preexisting DM
has a significant impact on NSCLC in Asian men [42].
Moreover, it was reported that the stage at initial diag-
nosis, and serum albumin and LDH levels were signifi-
cant prognostic factors in NSCLC [9, 10, 12–14]. These
findings are generally in agreement with those of our
study.
This study has several limitations. First, it was a retro-
spective analysis. Therefore, to minimize biases, all con-
secutive patients treated within our institutes were
included in the analyses, and the patients’ original charts
were thoroughly reviewed. Second, we did not evaluate
the type of DM, duration of diabetes and the types of
diabetic therapy used. Third, our findings may have a
Table 5 Association between DM and other prognostic factors from univariate analysis
DM (−) DM (+) p value
Gender Male 98 28 0.01a
Female 31 2
Age, median (range) 64 (40–75) 64.5 (49–74) 0.44b
Performance status 0 72 18 0.51a
1 56 11
2 1 1
Stage IIIA 70 16 0.92a
IIIB 59 14
Histology Adenocarcinoma 71 16 0.76a
Squamous cell carcinoma 45 9
Large cell carcinoma 4 2
Others 9 3
Smoking history Current or former 95 24 0.22a
Never 23 2
Unknown 11 4
Body mass index (BMI) (kg/m2) BMI < 18.5 13 2 0.69a
18.5 ≤ BMI <25 94 22
25 ≤ BMI < 30 20 6
BMI≥ 30 2 0
Laboratory parameters, median b
White blood cell, cells/μl 7060 (2950–22310) 7275 (4290–13580) 0.67
Hemoglobin, g/l 13.4 (8.7–17.2) 13.6 (7.2–16.0) 0.49
Albumin, g/dl 4.1 (2.4–4.8) 4.0 (3.2–4.9) 0.71
AST, U/l 20 (11–60) 20.5 (11–50) 0.32
ALT, U/l 18 (5–67) 22.5 (9–63) 0.16
LDH, U/l 187 (121–591) 208 (135–1120) 0.05
Calcium, mg/dl 9.0 (7.6–10.6) 9.05 (8.2–9.9) 0.59
Creatinine, mg/dl 0.71 (0.4–1.28) 0.73 (0.48–1.23) 0.43
Glucose, mg/dl 100 (62–144) 118 (85–230) <0.001
DM Diabetes mellitus, AST Alanine aminotransferase, AST Aspartate aminotransferase, LDH Lactate dehydrogenase
aFisher's exact test; bWilcoxon rank sum test; Boldfaced p-values are statistically significant (p < 0.05)
Table 6 Multivariate Cox regression analysis for gender, stage,
presence of diabetes mellitus, hemoglobin, serum albumin level,
serum LDH level and plasma glucose level
Overall survival
Factors Hazard ratio 95 % CI p value
Gender 1.16 0.67–2.07 0.584
Stage 1.75 1.16–2.65 0.007
Diabetes mellitus 1.91 1.09–3.23 0.024
Hemoglobin 0.94 0.81–1.09 0.444
Albumin 0.46 0.26–0.81 0.007
LDH 1.00 1.00–1.01 0.005
Glucose 0.99 0.98–1.00 0.063
95 % CI 95 % confidence interval, LDH Lactate dehydrogenase,
Boldfaced p-values are statistically significant (p < 0.05)
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selection bias because of the possibility of undiagnosed
DM among patients classified as not having DM.
Conclusions
In conclusion, the presence of DM at the time of diag-
nosis was identified as an independent and significant
prognostic factor for worse survival in locally advanced
NSCLC patients. Our findings also suggest that the pres-
ence of DM can help predict survival after CRT and is
useful for selecting the most appropriate treatment.
Therefore, a prospective large-scale trial is warranted to
confirm the results of our study.
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